These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28600618)

  • 1. Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis.
    Xie X; Li F; Li S; Tian J; Chen JW; Du JF; Mao N; Chen J
    Clin Rheumatol; 2018 Jan; 37(1):13-23. PubMed ID: 28600618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
    Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
    BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis.
    Thomson TM; Lescarbeau RM; Drubin DA; Laifenfeld D; de Graaf D; Fryburg DA; Littman B; Deehan R; Van Hooser A
    BMC Med Genomics; 2015 Jun; 8():26. PubMed ID: 26036272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis.
    Aterido A; Cañete JD; Tornero J; Blanco F; Fernández-Gutierrez B; Pérez C; Alperi-López M; Olivè A; Corominas H; Martínez-Taboada V; González I; Fernández-Nebro A; Erra A; López-Lasanta M; López Corbeto M; Palau N; Marsal S; Julià A
    Front Immunol; 2019; 10():1459. PubMed ID: 31312201
    [No Abstract]   [Full Text] [Related]  

  • 5. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
    Fafá BP; Louzada-Junior P; Titton DC; Zandonade E; Ranza R; Laurindo I; Peçanha P; Ranzolin A; Hayata AL; Duarte A; Silveira IG; Costa I; Macieira JC; Guedes-Barbosa LS; Bertolo MB; Sauma MF; Silva MB; Freire M; Scheinberg MA; Fernandes V; Bianchi W; Miranda JR; Pinheiro GR; Carvalho HM; Brenol CV; Pereira IA; de Castro GR; de Morais JC; Oliveira SK; de Abreu MM; Toledo RA; Pinheiro MM; Vieira WP; Valim V;
    Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review.
    Liang SJ; Zheng QY; Yang YL; Yang Y; Liu CY
    Rheumatol Int; 2017 Jul; 37(7):1207-1212. PubMed ID: 28255643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.
    Umekita K; Umeki K; Miyauchi S; Ueno S; Kubo K; Kusumoto N; Takajo I; Nagatomo Y; Okayama A
    Mod Rheumatol; 2015 Sep; 25(5):794-7. PubMed ID: 24252020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.
    Eng GP
    Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis.
    Fisher A; Bassett K; Goel G; Stanely D; Brookhart MA; Freeman HR; Wright JM; Dormuth CR
    PLoS One; 2016; 11(12):e0168005. PubMed ID: 27930739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VARIAR Study: Assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist.
    Torrente-Segarra V; Acosta Pereira A; Morla R; Ruiz JM; Clavaguera T; Figuls R; Corominas H; Geli C; Roselló R; de Agustín JJ; Alegre C; Pérez C; García A; Rodríguez de la Serna A
    Reumatol Clin; 2016; 12(6):319-322. PubMed ID: 26831256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis.
    Corrado A; Di Bello V; d'Onofrio F; Maruotti N; Cantatore FP
    Int J Immunopathol Pharmacol; 2017 Sep; 30(3):302-307. PubMed ID: 28604144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.
    Gonzalez-Gay MA; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Llorca J
    Ann N Y Acad Sci; 2010 Apr; 1193():153-9. PubMed ID: 20398022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profile predicting the response to anti-TNF treatment in patients with rheumatoid arthritis; analysis of GEO datasets.
    Kim TH; Choi SJ; Lee YH; Song GG; Ji JD
    Joint Bone Spine; 2014 Jul; 81(4):325-30. PubMed ID: 24561023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents.
    Detorakis EE; Magkanas E; Lasithiotaki I; Sidiropoulos P; Boumpas DT; Gourtsoyiannis N; Antoniou K; Raissaki M
    Clin Exp Rheumatol; 2017; 35(1):43-52. PubMed ID: 27908307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.